Clinical Trials Browser

Phase 2 × Leukemia, Myeloid, Acute × asparaginase erwinia chrysanthemi recombinant × Clear all

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04326439 2022-06-15

AflacLL1901 (CHOA-AML)

Phase 2 Terminated

8 enrolled 12 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02718755 2018-06-26

Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies

Phase 2 Withdrawn

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Recurrence, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02419755 2018-03-07

Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies

Phase 2 Terminated

12 enrolled 10 charts

LymphoidOther hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

AflacLL1901 (CHOA-AML)

Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies

Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies